A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma
作者： Gwi-Moon Seo , Raja Shekar Rachakatla , Sivasai Balivada , Marla Pyle , Tej B. Shrestha
DOI: 10.1007/S11033-011-0720-7
关键词:
摘要: Gene-directed enzyme prodrug therapy (GDEPT) has been investigated as a means of cancer treatment without affecting normal tissues. This system is based on the delivery suicide gene, gene encoding an which able to convert its substrate from non-toxic cytotoxin. In this experiment, we have developed targeted therapeutic that completely contained within tumor-tropic cells and tested for melanoma in preclinical model. First, established double stable RAW264.7 monocyte/macrophage-like (Mo/Ma) containing Tet-On® Advanced intracellular carboxylesterase (InCE) expression. Second, loaded into cells, Mo/Ma. Third, activated prodrug, irinotecan, cytotoxin, SN-38. Our Mo/Ma homed lung melanomas after 1 day successfully delivered prodrug-activating enzyme/prodrug package tumors. We observed our significantly reduced tumor weights numbers activation InCE. Therefore, propose may be useful pulmonary metastatic tumors with minimal side effects, particularly if it combined other treatments.
springer.com
sci-hub.se 参考文章(42)
Kazuhiko Arimori, Noriaki Kuroki, Ayumi Kumamoto, Naomi Tanoue, Masahiro Nakano, Eiji Kumazawa, Akiko Tohgo, Masahiko Kikuchi, Excretion into gastrointestinal tract of irinotecan lactone and carboxylate forms and their pharmacodynamics in rodents Pharmaceutical Research. ,vol. 18, pp. 814- 822 ,(2001) , 10.1023/A:1011040529881
M. Eileen Dolan, Rod Humerickhouse, Michael H. Wu, Bingfang Yan, Irinotecan activation by human carboxylesterases in colorectal adenocarcinoma cells. Clinical Cancer Research. ,vol. 8, pp. 2696- 2700 ,(2002)
Bernard Burke, Athina Giannoudis, Kevin P. Corke, Dalvir Gill, Michael Wells, Loems Ziegler-Heitbrock, Claire E. Lewis, Hypoxia-Induced Gene Expression in Human Macrophages: Implications for Ischemic Tissues and Hypoxia-Regulated Gene Therapy American Journal of Pathology. ,vol. 163, pp. 1233- 1243 ,(2003) , 10.1016/S0002-9440(10)63483-9
W. F. Bosron, K. Lohrbach, Lin Li, R. Humerickhouse, M. E. Dolan, Characterization of CPT-11 Hydrolysis by Human Liver Carboxylesterase Isoforms hCE-1 and hCE-2 Cancer Research. ,vol. 60, pp. 1189- 1192 ,(2000)
Teruo Yokokura, Norimasa Kaneda, Hiroshi Nagata, Tomio Furuta, Metabolism and pharmacokinetics of the camptothecin analogue CPT-11 in the mouse. Cancer Research. ,vol. 50, pp. 1715- 1720 ,(1990)
Michael Andreeff, Matus Studeny, Richard E. Champlin, Isaiah J. Fidler, Claudia Zompetta, Frank C. Marini, Bone Marrow-derived Mesenchymal Stem Cells as Vehicles for Interferon-β Delivery into Tumors Cancer Research. ,vol. 62, pp. 3603- 3608 ,(2002)
Clayton W. Naeve, Peter J. Houghton, Pamela J. Cheshire, Cynthia A. Pawlik, Mary K. Danks, Lois B. Richmond, Erik J. Krull, Philip M. Potter, Christopher L. Morton, Comparison of activation of CPT-11 by rabbit and human carboxylesterases for use in enzyme/prodrug therapy. Clinical Cancer Research. ,vol. 5, pp. 917- 924 ,(1999)
Olga Greco, Gabi U. Dachs, Gene directed enzyme/prodrug therapy of cancer: historical appraisal and future prospectives. Journal of Cellular Physiology. ,vol. 187, pp. 22- 36 ,(2001) , 10.1002/1097-4652(2001)9999:9999<::AID-JCP1060>3.0.CO;2-H
Debby Reuveni, Drora Halperin, Ina Fabian, Galia Tsarfaty, Nadir Askenasy, Itamar Shalit, Moxifloxacin increases anti-tumor and anti-angiogenic activity of irinotecan in human xenograft tumors Biochemical Pharmacology. ,vol. 79, pp. 1100- 1107 ,(2010) , 10.1016/J.BCP.2009.12.001
K. S. Aboody, A. Brown, N. G. Rainov, K. A. Bower, S. Liu, W. Yang, J. E. Small, U. Herrlinger, V. Ourednik, P. McL. Black, X. O. Breakefield, E. Y. Snyder, Neural stem cells display extensive tropism for pathology in adult brain: evidence from intracranial gliomas. Proceedings of the National Academy of Sciences of the United States of America. ,vol. 97, pp. 12846- 12851 ,(2000) , 10.1073/PNAS.97.23.12846